

**WEST****End of Result Set** [Generate Collection](#) [Print](#)

L1: Entry 1 of 1

File: DWPI

Aug 1, 1996

DERWENT-ACC-NO: 1996-362635

DERWENT-WEEK: 199636

COPYRIGHT 2002 DERWENT INFORMATION LTD

**TITLE:** Low mol. wt. lipo-polysaccharide from Pantoea or Salmonella - has high safety and high biological activity for pharmaceutical use, e.g. against toxoplasmosis and hypcholesterolaemia, anticancer and antidiabetic agent

**INVENTOR:** MIZUNO, D; NISHIZAWA, T ; SOMA, G

**PRIORITY-DATA:** 1995JP-0012126 (January 27, 1995)

**PATENT-FAMILY:**

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO <u>9623002</u> A1	August 1, 1996	J	032	C08B037/00
JP 08198902 A	August 6, 1996		011	C08B037/00

**INT-CL (IPC):** A61 K 31/715; C08 B 37/00; C12 P 19/04; C12 P 19/04; C12 R 1:42; C12 P 19/04; C12 R 1:01; C12 P 19/04; C12 R 1:42

**ABSTRACTED-PUB-NO:** WO 9623002A

**BASIC-ABSTRACT:**

Low mol. wt. lipopolysaccharide of microbial origin (LP) has the following properties: (a) mol.wt. 5000 (plus or minus 2000) by SDS-PAGE using protein markers, the material being substantially free from fractions of other mol.wt.; (b) 1-3 hexosamine units/mol. (5000 mol.wt. by Elson-Morgan method); (c) 1-3 2keto-3-deoxy-octonate units/mol. (5000 mol.wt. by the diphenylamine method); (d) limulus activity of 10 EU/ng, and (e) protein content and nucleic acid content each <1% (wt.).

**USE** - (LP) can be used as a pharmaceutical, e.g. against toxoplasmosis, as hypcholesterolaemia, anti-herpes, anti-rheumatic, anti-diabetic, immuno-modulator, anti-cancer, anti-gastric ulcer or anti-haemorrhoid agent. (LP) should be administered at 1 mug-100 mg orally or 10 ng-10 mg parenterally/day.

**ADVANTAGE** - (LP) has a high safety factor (low toxicity) and high biological activity.

**ABSTRACTED-PUB-NO:** WO 9623002A

**EQUIVALENT-ABSTRACTS:**

**CHOSEN-DRAWING:** Dwg.0/2